Robust quality control (QC) and release testing are essential to ensuring the safety, consistency, and clinical performance of live biotherapeutic products (LBPs). Unlike conventional biologics, LBPs consist of viable microorganisms whose identity, viability, and functional attributes must be tightly controlled across development and manufacturing.

As LBPs advance toward clinical and commercial stages, developers face increasing analytical complexity driven by strain specificity, formulation variability, and evolving regulatory expectations. This makes fit-for-purpose QC strategies, rather than standard testing panels, critical to success.

• Oxygen sensitivity: Many strains require anaerobic or microaerophilic handling
• Matrix interference: Lyophilized or multi-strain formulations can affect recovery
• Viability assessment: Differentiating live vs. non-viable cells is method-dependent
• Strain-level identification: Closely related strains demand high-resolution tools
• Batch variability: Biological systems require carefully defined release criteria

A common pitfall is applying standard microbial testing frameworks without accounting for strain-specific growth behavior and recovery bias. In practice, reliable QC often depends on customized workflows, including optimized recovery conditions and strain-specific detection strategies. Creative Biolabs has experience designing such approaches to improve reproducibility and data confidence.

Aligning Methods with QC Objectives
Effective QC depends on matching analytical methods to product attributes:

• Identity: WGS and strain-specific qPCR for precise strain confirmation
• Viability: Plate counting for CFU-based release, complemented by flow cytometry where appropriate
• Purity: Microbial limits, objectionable organisms, and, where relevant, mycoplasma and endotoxin testing
• Stability: Real-time studies for shelf life, supported by accelerated data for early decisions

In practice, method selection is product-specific. Creative Biolabs supports developers in defining appropriate combinations based on strain characteristics, formulation, and development stage.

Defining Release Testing Strategy
A robust release framework distinguishes between:

• Release-critical attributes: identity, viable count (potency), and key safety indicators
• Supporting data: functional assays and extended characterization

Mapping analytical data to release decisions is essential for both product consistency and regulatory alignment. Creative Biolabs works with developers to establish scientifically justified and operationally feasible specifications.

• Consistent strain identity and performance
• Reliable viable count data
• Stability-supported shelf life
• Appropriately validated methods

Creative Biolabs provides tailored documentation packages to support regulatory submissions, aligned with program stage and requirements.

For developers evaluating QC and release strategies for LBPs, Creative Biolabs provides customized analytical workflows tailored to strain characteristics, formulation types, and regulatory stage, supporting programs from early research through clinical development. More details are available on the Creative Biolabs LBP platform.

Frequently Asked Questions

Q1: What makes LBP QC different from conventional microbial testing?
LBP QC focuses on characterizing specific, functional strains, including strain-level identification and accurate viability assessment under controlled conditions.

Maintaining viability and performance throughout the intended shelf life depends on strain properties, formulation, processing, and storage. Target specifications are defined case by case based on product and clinical needs.